Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Osimertinib - AstraZeneca

Drug Profile

Osimertinib - AstraZeneca

Alternative Names: [11C]AZD9291; [11C]osimertinib; AZD-9291; Mereletinib; TAGRISSO

Latest Information Update: 12 May 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Dana-Farber Cancer Institute; Eli Lilly and Company; European Organisation for Research and Treatment of Cancer; European Thoracic Oncology Platform; G1 Therapeutics; Incyte Corporation; Kyushu University; Molecular Partners AG; National Cancer Institute (USA); National University Hospital (Singapore); Princess Margaret Hospital (University of Toronto); Singapore Clinical Research Institute; Sunnybrook Health Sciences Centre; University of California at San Francisco
  • Class Acrylamides; Aniline compounds; Antineoplastics; Dimethylamines; Indoles; Pyrimidines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Glioblastoma; Meningeal carcinomatosis
  • Phase I Solid tumours

Most Recent Events

  • 22 Apr 2020 AstraZeneca plans a phase III for Non-small cell lung cancer (Neoadjuvant therapy, Monotherapy, Combination therapy, First-line therapy) (NCT04351555)
  • 05 Mar 2020 Kyushu University in collaboration with AstraZeneca completes the phase II TAKUMI trial in Non-small cell lung cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater, Combination therapy) in Japan (PO) (UMIN000024438)
  • 26 Feb 2020 AstraZeneca completes the phase III FLAURA trial in Non-small cell lung cancer (Late stage disease, First-line therapy) in USA, Canada, United Kingdom, Hungary, Italy, Germany, Romania, France, Spain, Belgium, Czech Republic, Bulgaria, Poland, Switzerland, Russia, Ukraine, Thailand, Taiwan, Philippines, South Korea, Japan, Turkey, Australia, Brazil, China, Israel, Malaysia, Portugal, Saudi Arabia, Sweden and Vietnam (NCT02296125) (AstraZeneca pipeline, February 2020)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top